Clinical trial
The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Patients With Moderate Hypertension
NCT00095550 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Patients With Moderate Hypertension
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2004
- Completion date
- June 30, 2005
- Enrollment
- 496 (estimated)
- Sites
- 128
Conditions
As the registry lists them; a condition with its own page is linked.